Table 1.
Subject baseline demographics (SES).
| Short Flex (n = 142) | Long Flex (n = 140) | Total (N = 282) | |
|---|---|---|---|
| Sex, n (%) | |||
| Male | 36 (25.4) | 42 (30.0) | 78 (27.7) |
| Female | 106 (74.6) | 98 (70.0) | 204 (72.3) |
| Age, mean (SD) [range], y | 57.4 (10.6) [24–79] | 56.7 (11.3) [31–81] | 57.1 (11.0) [24–81] |
| Ethnicity, n (%) | |||
| Hispanic or Latino | 6 (4.2) | 6 (4.3) | 12 (4.3) |
| Not Hispanic or Latino | 136 (95.8) | 134 (95.7) | 270 (95.7) |
| Race, n (%) | |||
| White | 130 (91.5) | 128 (91.4) | 258 (91.5) |
| Black or African | 7 (4.9) | 7 (5.0) | 14 (5.0) |
| Other | 5 (3.5) | 5 (3.6) | 10 (3.5) |
| Height, mean (SD), cm | 166.8 (9.5) | 167.4 (9.7)a | 167.1 (9.6)b |
| BMI, mean (SD), kg/m2 | 27.9 (6.1) | 28.1 (5.4)a | 28.0 (5.8)b |
| Cumulative lifetime dose of BoNT pretreatment | |||
| OnabotulinumtoxinA | |||
| n | 130 | 135 | 265 |
| Units, mean (SD) | 4573 (5386) | 3979 (3867) | 4270 (4675) |
| AbobotulinumtoxinA | |||
| n | 18 | 13 | 31 |
| Units, mean (SD) | 2703 (3465) | 3065 (2665) | 2855 (3111) |
| IncobotulinumtoxinA | |||
| n | 14 | 7 | 21 |
| Units, mean (SD) | 906 (974) | 624 (1035) | 812 (978) |
| RimabotulinumtoxinB | |||
| n | 12 | 7 | 19 |
| Units, mean (SD) | 105,552 (176,036) | 40,750 (37,431) |
81,678 (142,955) |
BMI, body mass index; BoNT, botulinum neurotoxin; SD, standard deviation; SES, safety evaluation set. an = 139. bn = 281.